Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GLTO 
Galecto Inc (GLTO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/03/2025: GLTO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -82.78% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.70M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 2 | Beta 1.39 | 52 Weeks Range 2.01 - 18.45 | Updated Date 11/3/2025 |
52 Weeks Range 2.01 - 18.45 | Updated Date 11/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.33% | Return on Equity (TTM) -96.08% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3562988 | Price to Sales(TTM) - |
Enterprise Value -3562988 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.46 | Shares Outstanding 1324560 | Shares Floating 1316401 |
Shares Outstanding 1324560 | Shares Floating 1316401 | ||
Percent Insiders 3.68 | Percent Institutions 4.71 |
Upturn AI SWOT
Galecto Inc
Company Overview
History and Background
Galecto, Inc. is a biotechnology company focused on the discovery and development of novel treatments for fibrosis and cancer. Founded in 2011, it has progressed through various clinical trials, focusing on galectin inhibitors.
Core Business Areas
- Fibrosis Drug Development: Develops small molecule galectin inhibitors to treat fibrosis in organs like the liver and lungs.
- Cancer Immunotherapy: Explores galectin inhibitors' potential in enhancing cancer immunotherapy.
Leadership and Structure
Bertil Lindsten is the CEO. The company has a standard biotechnology organizational structure with departments for research, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- GB0139: An inhaled formulation of a galectin-3 inhibitor targeting idiopathic pulmonary fibrosis (IPF) and other respiratory diseases. It is in clinical development. Competitors include Boehringer Ingelheim's Ofev and Roche's Esbriet.
- GB1211: An oral galectin-3 inhibitor being developed for NASH and potentially other fibrotic conditions. It is in clinical trials. Competitors include numerous companies developing NASH therapies, such as Intercept Pharmaceuticals and Madrigal Pharmaceuticals.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically focusing on fibrosis and cancer therapies, is highly competitive and innovative. There is a high unmet need for effective treatments.
Positioning
Galecto is positioned as a specialized biotechnology company focusing on galectin inhibition. Its competitive advantage lies in its specific expertise in this area, but it faces competition from larger pharmaceutical companies.
Total Addressable Market (TAM)
The combined TAM for IPF, NASH, and cancer immunotherapy is estimated to be in the tens of billions of USD. Galecto is aiming to capture a share of this market through its novel therapies.
Upturn SWOT Analysis
Strengths
- Novel galectin inhibitor technology
- Experienced management team
- Focus on unmet medical needs
- Clinical stage assets
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial success
- Potential for regulatory hurdles
- History of financial losses.
Opportunities
- Potential for partnerships with larger pharmaceutical companies
- Expansion into new indications
- Positive clinical trial results
- Growing market for fibrosis and cancer therapies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory setbacks
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- BI (Boehringer Ingelheim)
- Roche
- Intercept Pharmaceuticals
- Madrigal Pharmaceuticals
Competitive Landscape
Galecto is a smaller player compared to established pharmaceutical companies. It relies on its innovative technology and focus on galectin inhibition to compete.
Growth Trajectory and Initiatives
Historical Growth: Data not available without current source.
Future Projections: Future growth is dependent on clinical trial successes and potential partnerships.
Recent Initiatives: Focus on advancing GB0139 and GB1211 through clinical trials.
Summary
Galecto is a biotechnology company with promising galectin inhibitor technology but faces significant challenges due to limited resources and dependence on clinical trial outcomes. The company's focus on fibrosis and cancer provides opportunities for growth, but competition from larger pharmaceutical companies poses a threat. Success hinges on positive clinical data and strategic partnerships.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings, press releases, analyst reports (where available)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Galecto Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-10-29 | Co-Founder, President, CEO & Director Dr. Hans T. Schambye M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://galecto.com |
Full time employees 5 | Website https://galecto.com | ||
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.